Latest papers

Mast cells in health and disease: from basic science to clinical application 4-5 July 2008, Stuttgart, Germany.

Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.

Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.

Pulmonary mastocytosis and enhanced lung inflammation in mice heterozygous null for the Foxf1 gene.

Mast cells and mastocytosis.

Pediatric mastocytosis: routine anesthetic management for a complex disease.

The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells.

An approach to the patient with urticaria.

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Quantifying mast cells in bladder pain syndrome by immunohistochemical analysis.

Advances in basic and clinical immunology in 2007.

Systemic mastocytosis with plasma cell dyscrasia: report of a case.

Immunohistochemical Application of an Antibody Specific for Human CD1a to the Diagnosis of Canine Mast Cell Tumour

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.

The mast cell and allergic diseases: role in pathogenesis and implications for therapy.

Increased intestinal endotoxin absorption during enteric nematode but not protozoal infections through a mast cell-mediated mechanism.

What is your diagnosis? Cutaneous mastocytosis (urticaria pigmentosa).

Iatrogenic xanthoderma.

IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity.

High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.